Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK7 | Q13164 | 2/20 | 0.71 |
| ▸ | PLK1 | P53350 | 16/20 | 0.60 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.60 |
| ▸ | PLK3 | Q9H4B4 | 11/20 | 0.44 |
| ▸ | PLK2 | Q9NYY3 | 10/20 | 0.44 |
| ▸ | BRD4 | O60885 | 6/20 | 0.43 |
| ▸ | BRDT | Q58F21 | 3/20 | 0.43 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | PRKCG | P05129 | 1/20 | 0.42 |
| ▸ | CLK2 | P49760 | 1/20 | 0.42 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.42 |
| ▸ | NEK4 | P51957 | 1/20 | 0.42 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.42 |
| ▸ | CAMK2G | Q13555 | 1/20 | 0.42 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.42 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.42 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10098782 | 1.00 | MAPK7 (0.71) | MAPK7PLK1DYRK1APLK3PLK2 | |
| SCHEMBL618023 | 0.83 | MAPK7 (1.00) | MAPK7PLK1DYRK1APLK3PLK2 | |
| SCHEMBL10098798 | 0.83 | MAPK7 (1.00) | MAPK7PLK1DYRK1APLK3PLK2 | |
| SCHEMBL19105505 | 0.79 | MAPK7 (0.46) | MAPK7PLK1PLK3PLK2BRD4 | |
| SCHEMBL18271784 | 0.77 | MAPK7 (0.81) | MAPK7PLK1DYRK1APLK3PLK2 | |
| SCHEMBL616340 | 0.75 | PLK1 (1.00) | MAPK7PLK1DYRK1APLK3PLK2 | |
| SCHEMBL10098775 | 0.75 | PLK1 (1.00) | MAPK7PLK1DYRK1APLK3PLK2 | |
| SCHEMBL618641 | 0.74 | PLK1 (0.69) | MAPK7PLK1DYRK1APLK3PLK2 | |
| SCHEMBL10098781 | 0.74 | PLK1 (0.69) | MAPK7PLK1DYRK1APLK3PLK2 | |
| SCHEMBL10098789 | 0.74 | PLK1 (0.75) | MAPK7PLK1DYRK1APLK3PLK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180362545-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-12-20 | — | — | US | claimed |
| US-20120040961-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE (US) | 2012-02-16 | — | — | US | claimed |
| EP-3828185-A2 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | Dana Farber Cancer Institute, Inc. (US) | 2021-06-02 | — | — | EP | disclosed |
| US-10383847-B2 | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo | BROWN DENNIS M (US) | 2019-08-20 | — | — | US | disclosed |
| US-20160243077-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | BROWN DENNIS M (US) | 2016-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040961-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | BRSK2, BRSK1, TAOK3 | MAPK7 263/4885PLK1 109/4885DYRK1A 363/4885 |
| US-10383847-B2 | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo | NEK9, NEK7, NEK3 | MAPK7 295/4885PLK1 31/4885DYRK1A 670/4885 |
| US-20180362545-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | BRSK2, STK3, BRSK1 | MAPK7 253/4885PLK1 110/4885DYRK1A 350/4885 |
| US-20160243077-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | NEK9, NEK7, NEK3 | MAPK7 295/4885PLK1 31/4885DYRK1A 670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.